

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

GENOME THERAPEUTICS CORP

Form 8-K

July 02, 2001

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to
Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): June 27, 2001

GENOME THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

MASSACHUSETTS

0-10824

04-2297484

(State or other jurisdiction of incorporation) (Commission File Number)

(I.R.S. Employer Identification Number)

100 BEAVER STREET
WALTHAM, MASSACHUSETTS 02453

(Address, of principal executive offices, including zip code)

(781) 398-2300

(Registrant's Telephone number including area code)

PAGE 1 OF 4 PAGES.

Item 5. OTHER EVENTS

Genome Therapeutics Corp. has entered into an engagement letter with Tucker Anthony Sutro to retain Tucker Anthony as our non-exclusive agent in connection with the sale of up to 1,950,000 registered shares of Genome Therapeutics.

Edgar Filing: GENOME THERAPEUTICS CORP - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.

By /s/ STEPHEN COHEN

Name: Stephen Cohen
Title: Chief Financial Officer

Date: July 2, 2001

EXHIBIT INDEX

- 1.1 Form of Engagement Letter between Genome Therapeutics Corp. and Tucker Anthony Sutro.